Shows
NeurologyLive® Mind Moments®Navigating Transition: Supporting Young Adults With Epilepsy Into Adult CareWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, "Navigating Transition: Supporting Young Adults With Epilepsy Into Adult Care," Danielle Andrade, MD, MSc, adult neurologist at the University of Toronto and co-chair of the ILAE Transition Task Force, discussed the critical process of moving pediatric patients with epilepsy into adult care. She highlighted findings from the task force’s global survey on transition practices, revealing major differences across regions. Andrade also shared important considerations for students with epilepsy entering college, including life...
2025-08-2213 minNeurologyLive® Mind Moments®Improving Quality of Life in Movement Disorders Through Nonmotor Symptom ManagementWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, "Improving Quality of Life in Movement Disorders Through Nonmotor Symptom Management" Alex Dessy, MD, clinical assistant professor in movement disorders at Jefferson Health, shares a comprehensive look at modern-day care strategies for patients with Parkinson disease and other movement disorders. Dessy discusses the foundational role of detailed history-taking, exam-based observation, and phenomenology in diagnosing complex conditions, along with the growing utility of genetic and imaging tools. She also explains the challenges of ma...
2025-08-0817 minNeurologyLive® Mind Moments®Overviewing Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer CareWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, "Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer’s Care" John Sims, MD, head of medical development for donanemab at Eli Lilly and Company, joins NeurologyLive to discuss the recently updated label for donanemab (Kisulna), an anti-amyloid Alzheimer disease (AD) therapy. Sims breaks down the key safety data from the TRAILBLAZER-ALZ-6 study (NCT05738486) that led to a newly approved titration-based dosing regimen aimed at minimizing ARIA risk. He outlines considerations for cl...
2025-07-2517 minNeurologyLive® Mind Moments®Breaking Down the FDA’s Latest Migraine Therapy Approvals with Dr. Stewart TepperWelcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this special FDA-focused episode of Mind Moments, migraine expert Stewart Tepper, MD, professor of neurology at the Geisel School of Medicine at Dartmouth, discusses the recent FD...
2025-07-1826 minNeurologyLive® Mind Moments®Rewiring Stroke Recovery: What the Glymphatic System Can Teach UsWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, "Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead," Joyce Lee-Iannotti, MD, PhD, division chief of both the Stroke Center and the Comprehensive Sleep Center at Barrow Neurological Institute, discusses her presentation from the 2025 SLEEP Annual Meeting focused on the glymphatic system’s role in stroke. She outlines the science behind this brain-cleansing pathway, its dependence on sleep quality, and how its dysfunction may worsen outcomes in both ischemic and hemorrhagic stroke...
2025-07-1117 minNeurologyLive® Mind Moments®Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s AheadWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, "Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead," Joseph Sullivan, MD, director of the Pediatric Epilepsy Center at UCSF, joins Mind Moments to discuss the clinical distinctions between Dravet syndrome and Lennox-Gastaut syndrome (LGS). Sullivan outlines the unique diagnostic profiles, seizure presentations, and genetic underpinnings of each disorder, while also addressing how genetic testing has transformed the approach to Dravet syndrome in particular. He speaks on the future of targeted ther...
2025-06-2717 minNeurologyLive® Mind Moments®Bemdaneprocel and the Future of Cell Therapy in Parkinson DiseaseWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, "Bemdaneprocel and the Future of Cell Therapy in Parkinson Disease" Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center, discusses the phase 3 exPDite-2 trial evaluating bemdaneprocel, an investigational cell therapy for Parkinson disease (PD). Pahwa explains the rationale behind cell replacement therapy as a means to restore dopamine production, outlining the progression from fetal tissue implants to stem cell–derived dopaminergic neuron...
2025-06-1315 minNeurologyLive® Mind Moments®World MS Day: Raising Awareness, Evolving Care, and Empowering PatientsWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, "World MS Day: Raising Awareness, Evolving Care, and Empowering Patients," Taylor Hess, MD, a multiple sclerosis specialist at the Michigan Institute for Neurological Disorders (MIND), shares insights in recognition of World MS Day. She reflects on the importance of raising global awareness for MS, the need for equitable care, and the evolving focus of research and treatment. Dr. Hess discusses underrecognized symptoms like fatigue and cognitive dysfunction, and emphasizes the value of th...
2025-05-3012 minNeurologyLive® Mind Moments®Refining TSC Care: Phenotyping, Clustering, and Clinical ImpactWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, "Refining TSC Care: Phenotyping, Clustering, and Clinical Impact," Ajay Gupta, MD, director of the Tuberous Sclerosis Program at Cleveland Clinic, discusses recently published research that used unsupervised clustering to group over 900 patients with tuberous sclerosis complex (TSC) into four clinically meaningful phenotypic clusters. He outlines the distinct traits of each cluster—ranging from tumor risk to cognitive impairment—and explains how variant-specific genetic data helped reinforce these categories. Gupta, who also serves as a p...
2025-05-1622 minNeurologyLive® Mind Moments®Down Syndrome and Alzheimer’s: Clinical Trials, Equity, and Patient-Centered ProgressWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, "Down Syndrome and Alzheimer’s: Clinical Trials, Equity, and Patient-Centered Progress," Elizabeth Head, PhD, professor in the department of Pathology and Laboratory Medicine at the University of California, Irvine, discussed the evolving intersection of Down syndrome and Alzheimer disease using updates from the Alzheimer Biomarker Consortium – Down Syndrome (ABC-DS). She detailed how outcome assessments have been refined to meet the unique cognitive profiles of individuals with Down syndrome and shared the progress in lau...
2025-05-0220 minNeurologyLive® Mind Moments®Sleep and Seizures: Emerging Insights From AAN 2025Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, "Sleep and Seizures: Emerging Insights From AAN 2025," Nancy Foldvary-Schaefer, DO, director of the Sleep Disorders Center at Cleveland Clinic, reflected on key sleep-related topics presented at this year’s AAN Annual Meeting. She highlighted the growing clinical interest in underrecognized conditions like idiopathic hypersomnia and narcolepsy, stressing the need for better awareness and earlier diagnosis. Foldvary-Schaefer also detailed the development of the Sleep by Cleveland Clinic mobile app, designed to improve screening for...
2025-04-1825 minNeurologyLive® Mind Moments®Special Episode: What Apomorphine Infusion Approval Means for Parkinson Disease CareWelcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we cover the recent approval of Supernus Pharmaceuticals' agent SPN-830, marketed as Onapgo, as the first and only subcutaneous apomorphine infusion device for the tr...
2025-03-2717 minNeurologyLive® Mind Moments®Advancing Neuromuscular Care and ResearchWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, "Advancing Neuromuscular Care and Research," former FDA commissioner Robert Califf, MD, explored the urgent need for sustained NIH funding to advance basic and translational research, including gene editing, assistive devices, and the integration of artificial intelligence. He emphasized the collaborative spirit of the neuromuscular community, where shared technologies and insights can address multiple disorders. The conversation, which took place at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific conference, highlighted critical challenges, such as...
2025-03-2110 minNeurologyLive® Mind Moments®Special Episode: FDA Approves Tenecteplase for Acute Ischemic StrokeWelcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we cover the recent approval of Genentech's tenecteplase, marketed as TNKase, as a new treatment for adults with acute ischemic stroke (AIS). The thrombolytic me...
2025-03-1218 minNeurologyLive® Mind Moments®Raising Epilepsy Awareness for Purple DayWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Sonal Bhatia, MD, FACNS, epilepsy expert and director of the pediatric epilepsy monitoring unit (EMU) at the Medical University of South Carolina, discussed Purple Day, celebrated on March 25th, and the importance of raising awareness for patients with epilepsy, a common condition affecting one in 26 individuals. She discussed the stigma faced by patients with epilepsy, especially in parts of the world outside the United States. Bhatia also discussed some of the recent ad...
2025-03-0724 minNeurologyLive® Mind Moments®Invaluable Role of Social Support in Narcolepsy and Idiopathic Hypersomnia CareWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Julie Flygare, JD, president and chief executive officer of Project Sleep, shared her personal and professional insights into the critical role of social connections for patients living with narcolepsy and idiopathic hypersomnia. Drawing from her journey with narcolepsy, Flygare highlighted the challenges of isolation at diagnosis and the transformative power of peer support and advocacy. She delved into survey findings that underscore the rarity of social connections among patients and their impact on...
2025-02-2116 minNeurologyLive® Mind Moments®Previewing the 2025 ACTRIMS ForumWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Veronique Miron, PhD, The John David Eaton Chair in Multiple Sclerosis at the University of Toronto, gave a clinical overview of the 2025 ACTRIMS Forum, which is held February 27-March 1, in West Palm Beach, Florida. Miron, an expert in the field, spoke on the reasons behind this year's theme of "Making Connections," as well as some of the most notable and innovative sessions attending clinicians should keep their eyes on. Additionally, she spoke on...
2025-02-0715 minNeurologyLive® Mind Moments®Clinical Guidance on Neurostimulation for Lennox-Gastaut SyndromeWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, epilepsy expert Depobam Samanta, MD, MS, FAAP, FAES, sat down to discuss a recently published guidance paper from members of the Pediatric Epilepsy Research Consortium that provides recommendations for neuromodulation approaches to treat Lennox-Gastaut syndrome (LGS). Samanta, medical director of the Arkansas Children's Comprehensive Epilepsy Program, gave a clinical overview of the paper, highlighting the various neuromodulatory devices and their use, and the ways to improve treatment selection and personalization. Additionally, he ta...
2025-01-2425 minNeurologyLive® Mind Moments®Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker TestWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Russ Lebovitz, MD, PhD, chief executive officer and cofounder of Amprion, discussed the company's SAAmplify-aSYN biomarker test, a first-in-class qualitative laboratory developed test and the only seed amplification assay available to aid in the diagnosis of synucleinopathies such as Parkinson disease (PD) and multiple system atrophy (MSA). Lebovitz provided insight on the new technology and its remarkable accuracy in identifying underling a-synuclein pathology using fluorescence changes. He gave a complete overview of th...
2025-01-1022 minNeurologyLive® Mind Moments®Neurology Unwrapped: 2024’s Most Intriguing ConversationsWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this special episode, we’ve compiled some of the most compelling conversations from Mind Moments podcast episodes throughout 2024. These discussions spotlight groundbreaking research and advancements in neurology that are propelling the field forward. The NeurologyLive team also explored the impact of several newly FDA-approved therapies, offering clinicians valuable insights into what these treatments mean for patient care and their practical use in the clinic. Featured in this week’s episode, in order of appearance, are:
2024-12-2725 minNeurologyLive® Mind Moments®The Promise Behind Cell Therapy Approaches in EpilepsyWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Jonathan Parker, MD, PhD, an assistant professor of neurosurgery at Mayo Clinic Arizona, spoke about the emerging commotion around cell therapies as a way to treat patients with epilepsy. The discussion, which took place at the 2024 American Epilepsy Society (AES) Annual Meeting in Los Angeles, California, covers the thought process behind this approach and why it may hold greater advantages over other traditional surgeries that result in detrimental cognitive effects. Parker, director of...
2024-12-1323 minNeurologyLive® Mind Moments®Implications of the 2024 AASM Guidelines for Restless Legs SyndromeWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Andy Berkowski, MD, PhD, founder of Relax Health, sat down to discuss the American Academy of Sleep Medicine's (AASM) recently published guideline update for the treatment of restless legs syndrome (RLS). Berkowski, who serves as a vice chair of the AASM's Practice Guidelines Task Force, provided clinical insight on the reasons behind the guidelines, pointing to the vast research advances and literature updates since its last iteration in 2012. Additionally, he touched on th...
2024-11-2924 minNeurologyLive® Mind Moments®Machine Learning Algorithms to Predict Seizure Control in Epilepsy SurgeryWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Lara Jehi, MD, MHCDS, an epilepsy specialist and Cleveland Clinic’s Chief Research and Information Officer, sat down to discuss a recently published study that explored using machine learning algorithms to predict seizure control after epilepsy surgery. In the interview, Jehi explained the unique aspects of the study design, emphasizing the importance of a large, well-characterized patient cohort with consistent follow-up and the choice of scalp EEG—a commonly used, non-invasive test in epi...
2024-11-1521 minNeurologyLive® Mind Moments®Adapting Neuromuscular and Electrodiagnostic Medicine Education for Modern LearnersWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Lawrence Robinson, MD, a senior scientist at Sunnybrook Research Institute, sat down to discuss his presentation from the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting, focused on educating the next generation of neuromuscular and electrodiagnostic (EDX) practitioners. Robinson gave an overview of his presentation, why this was a topic of interest, and the major differences in how this generation of medical students learn relative to previous ones. In addition, he...
2024-11-0115 minNeurologyLive® Mind Moments®Special Episode: FDA Approves Sodium Oxybate for Pediatric NarcolepsyWelcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we cover the recent approval of Avadel's sodium oxybate formulation (Lumryz) as a treatment for pediatric patients with narcolepsy aged 7 years and older. The ne...
2024-10-2312 minNeurologyLive® Mind Moments®Therapeutic Potential of ATH434 in Multiple System AtrophyWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Daniel Claaseen, MD, MS, a professor of neurology and chief of the Behavioral and Cognitive Neurology Division at Vanderbilt University Medical Center, offered his insight on phase 1/2 data that was recently presented at the International Parkinson and Movement Disorder Society (MDS) Congress on ATH434, an investigational drug in development from Alterity Therapeutics for multiple system atrophy (MSA). He dove into the therapy's mechanism of action and the currently known safety profile and co...
2024-10-1814 minNeurologyLive® Mind Moments®Understanding Major Changes to New McDonald Criteria for Multiple SclerosisWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Daniel Ontaneda, MD, PhD, a staff member of the Cleveland Clinic Mellen Center for Multiple Sclerosis, provided an in-depth overview on the newly announced McDonald criteria to diagnose multiple sclerosis (MS). Ontaneda, who also serves as an assistant professor of neurology, discussed the most notable changes to the criteria and how it may help towards improving rates of misdiagnosis and missed diagnosis. He spoke on the incorporation of new biomarkers, such as ce...
2024-10-0427 minNeurologyLive® Mind Moments®Therapeutic Updates and Progress in Treating Becker Muscular DystrophyWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Joanne Donovan, MD, PhD, chief medical officer at Edgewise Therapeutics, sat down to discuss the clinical program of EDG-5506, an investigational drug in development for Becker muscular dystrophy, and the recent progress in treating and understanding Becker muscular dystrophy. She spoke on the mechanism of action of the drug, also known as sevasemten, and why the company believes it can be therapeutically beneficial for this patient population. Furthermore, Donovan spoke on the pr...
2024-09-2019 minNeurologyLive® Mind Moments®Previewing Cleveland Clinic's Epilepsy SummitWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, epilepsy expert Imad Najm, MD, PhD, sat down to discuss the upcoming Cleveland Clinic Epilepsy Summit, an educational symposium that takes place September 11-15, in Cleveland, Ohio. Najm, who serves as the director of Cleveland Clinic's Epilepsy Center at the Cleveland Clinic Neurological Institute, spoke about the objectives and goals of the meeting, including updates on sEEG, epilepsy surgery, treatments for drug-resistant epilepsy, and gene therapy. In addition, he provided an ov...
2024-09-0622 minNeurologyLive® Mind Moments®RNA Therapeutics, Mivelsiran, and Treating Alzheimer DiseaseWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Sharon Cohen, MD, a behavioral neurologist, sat down to discuss positive data from an ongoing phase 1 study of mivelsiran (Alnylam Pharmaceuticals), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer disease (AD). Cohen, who also serves as the medical director of the Toronto Memory Program at the University of Toronto, discussed the potential of RNA therapeutics for treating AD, the unique mechanism of action of mivelsiran, and some of...
2024-08-2324 minNeurologyLive® Mind Moments®Understanding the Potential Cardiovascular Benefits of Low-Sodium OxybateWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Phil Jochelson, therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals, sat down to discuss the phase 4 XYLO study, a randomized controlled study evaluating the effects of switching from high-sodium to low-sodium oxybate on blood pressure in patients with narcolepsy. Jochelson gave some insight regarding the conduct of the trial, including end points, objectives, and patient demographics, as well as some of the benefits to studying blood pressure and cardiovascular risks. In...
2024-08-0920 minNeurologyLive® Mind Moments®Expanding Access to Ublituximab and AntiCD20s for Multiple SclerosisWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Michael Weiss, chief executive officer of TG Therapeutics, discussed ublituximab (Briumvi), a recently approved anti-CD20 therapy for relapsing multiple sclerosis, and the advantages it brings to patients. Specifically, he talked about the Department of Veteran Affairs' decision to award national contract to ublituximab as the preferred anti-CD20 for this patient population, and how this facilitates greater access to the treatment. In addition, he discussed how the knowledge profile of the agent ha...
2024-07-3125 minNeurologyLive® Mind Moments®Improving Gait in Multiple Sclerosis Through the Neural SleeveWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Douglas Wajda, PhD, an assistant professor of neurology at Cleveland State University, discussed a pilot study presented at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting using a functional electrical stimulation approach, Neural Sleeve, to treat gait in MS. Wajda, who has been studying gait in MS for several years, gave clinical insight on the functionality and feasibility of this approach, and the personalized treatment patients can gain from it. He...
2024-07-2613 minNeurologyLive® Mind Moments®Utilizing the Syn-One Test to Diagnose Parkinson DiseaseWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Sameea Husain-Wilson, DO, a movement disorder specialist at the Marcus Neuroscience Institute of Baptist Health, provided clinical perspective on the use of the Syn-One diagnostic test for patients with Parkinson disease (PD). She gave an overview of how the test is utilized in clinic, ways to interpret results, and the right personnel needed to ensure an accurate diagnosis. In addition, she provided clarity on the role of alpha-synuclein in PD, the ad...
2024-07-1219 minNeurologyLive® Mind Moments®Special Episode: FDA Approves Donanemab for Early Symptomatic Alzheimer DiseaseWelcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we're covering the recent approval of donanemab as a new treatment for adults with early symptomatic Alzheimer disease (AD). Marketed as Kisunla, donanemab's approval ma...
2024-07-0911 minNeurologyLive® Mind Moments®Gaining Patient Perspectives on Impact of NarcolepsyWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Anne Marie Morse, DO, FAAN, a pediatric neurologist and sleep medicine specialist at Geisinger Medical Center, sat down at the 2024 SLEEP Annual Meeting to discuss a poster presentation highlighting a listening analysis that characterized the struggles and unmet needs of people with narcolepsy. in the discussion, Morse outlined some of the major findings, including the rates of missed and misdiagnosis, how cataplexy impacts daily life, and some of the other comorbidities as...
2024-06-2818 minNeurologyLive® Mind Moments®2024 Consortium of Multiple Sclerosis Centers Annual Meeting HighlightsWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with a variety of specialists in neurology who presented research and gave talks at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, held May 29-June 2, in Nashville, Tennessee. Those included in this week's episode, in order of appearance, are:
Anthony Feinstein, PhD, FRCPC, MBBCh, a professor of psychiatry at the University of Toronto.
Brian G. Weinshenker, MD, a professor of neurology at the University of Virginia.
Douglas A...
2024-06-1422 minNeurologyLive® Mind Moments®Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse GliomasWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Katherine Peters, PhD, a neurologist and neurooncologist at the Preston Robert Tisch Brain Tumor Center at Duke University provided context on a new analysis from the phase 3 INDIGO trial, a study assessing vorasidenib in patients with mutant isocitrate dehydrogenase (mIDH) 1/2 diffuse gliomas. The conversation, which occurred at the 2024 AAN Annual Meeting, covered the covered the therapeutic potential of this agent and its impacts on quality of life, neurocognition, and seizure control. Pe...
2024-05-3113 minNeurologyLive® Mind Moments®Phase 3 PHOENIX Study, AMX0035, and Amylyx's Future Drug DevelopmentWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Justin Klee and Josh Cohen, cofounders and cochief executive officers of Amylyx Pharmaceuticals, sat down at the recently concluded AAN Annual Meeting to discuss the results from the pivotal phase 3 PHOENIX trial (NCT) of AMX0035 (Relyvrio) in patients with amyotrophic lateral sclerosis (ALS). The duo provided clarity on the findings, positive takeaways from the disappointing data, and the lessons learned in ALS drug development. In addition, the two provided commentary on th...
2024-05-0319 minNeurologyLive® Mind Moments®Special Episode: FDA Approval of Diazepam Buccal Film for Pediatric SeizuresWelcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we're covering the recent approval of diazepam buccal film (Libervant; Aquestive Therapeutics) for the treatment of pediatric patients with intermittent, stereotypic episodes of frequent se...
2024-05-0118 minNeurologyLive® Mind Moments®Lessons Learned in Alzheimer Drug DevelopmentWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Ian Kremer, executive director of the leaders Engaged on Alzheimer's Disease (LEAD) coalition, spoke about several relevant topics regarding Alzheimer care as new novel therapeutics emerge. He talked about the lessons learned from the recent discontinuation of aducanumab, and the potential and limitations lecanemab (Leqembi; Eisai) and donanemab (Eli Lilly) may bring. Additionally, he provided comments about what matters to patients, the perception of the FDA approval process, and what is considered "cl...
2024-04-1935 minNeurologyLive® Mind Moments®Special Episode: FDA Approval of SPN-830 for OFF Episodes in Parkinson DiseaseWelcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we're covering the recent approval of SPN-830, an apomorphine infusion device, as a new treatment for OFF episodes in patients with Parkinson disease (PD). Ma...
2024-04-0619 minNeurologyLive® Mind Moments®Exploring Dimethyl Fumarate to Treat Friedreich AtaxiaWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Francesco Saccà, MD, PhD, an associate professor of neurology at the University of Naples, discussed an ongoing study assessing the use of dimethyl fumarate, an approved therapy for relapsing multiple sclerosis, in patients with Friedreich ataxia (FA). He spoke on the mechanism of action of the agent and why it can be beneficial in this patient population, as well as how it differs from omaveloxolone (Skyclarys; Biogen), the first approved treatment for FA...
2024-04-0519 minNeurologyLive® Mind Moments®Special Episode: FDA Approval of Givinostat for Duchenne Muscular DystrophyWelcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we're covering the recent approval of givinostat (Duvyzat; Italfarmaco) for the treatment of Duchenne muscular dystrophy (DMD). The therapy, a proprietary histone deacetylase (HDAC) in...
2024-03-2912 minNeurologyLive® Mind Moments®Reviewing ACTRIMS 2024Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Daniel Ontaneda, MD, an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine, sat down to discuss the recently concluded Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. Ontaneda, program committee vice-chair of the meeting, provided insight on a number of notable sessions and discussions that highlighted the recent advances in the MS field. In addition, he talked about the need to innovate clinical trials, ways to...
2024-03-2230 minNeurologyLive® Mind Moments®Differential Diagnosis of Sleep Disorders and HypersomniasWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Alcibiades Rodriguez, MD, medical director of the Comprehensive Epilepsy Center—Sleep Center at NYU Langone discussed several sleep-related topics, including the diagnosis of rare sleep disorders and hypersomnias. He spoke on the treatment of obstructive sleep apnea, the importance of adherence to medication, and the ways clinicians can help patients stick to their treatment regimen. Furthermore, he talked about the conversations between patients and clinicians to ensure an accurate diagnosis, as well as t...
2024-03-0819 minNeurologyLive® Mind Moments®AB126, Exosomes, and Cerebroprotection for StrokeWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Stephen From, chief executive officer of Aruna Bio, sat down to discuss the company's investigational exosome candidate AB126 and its upcoming phase 1b/2a trial in patients with ischemic stroke. He discussed the mechanism of action of the therapy, the advantages of its anti-inflammatory and neuroprotective properties, and how it will be used with other stroke treatments. Furthermore, he gave insight on the complexities with conducting stroke trials and improving neurodegeneration in po...
2024-02-2322 minNeurologyLive® Mind Moments®Advancing the Genetic Pool of Parkinson DiseaseWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Ignacio Mata, PhD, sat down to discuss a recently published meta-analysis on the genetic backgrounds of Parkinson disease beyond traditional European populations. Mata, an associate professor in the Genomic Medicine Institute at Cleveland Clinic, provided insight on the newly identified novel loci and how the data adds to previous genome-wide association studies. In addition, he gave thoughts on the possibility of gene therapy and some of the barriers that come with it, as...
2024-02-0921 minNeurologyLive® Mind Moments®Revealing Mechanisms of Sudden Unexplained Death in ToddlersWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Orrin Devinsky, MD, director of the NYU Langone Comprehensive Epilepsy Center, provided commentary on a recently published study assessing video evidence of sudden unexplained deaths in toddlers. Devinsky, who also serves as a professor of neurology, discussed the importance behind crib cams, the moments captured prior to the deaths assessed, and the involvement of seizure activity even with no prior history. In addition, he spoke on the abnormal sounds and movements of th...
2024-01-2618 minNeurologyLive® Mind Moments®Potential Role of Stathmin-2 in Amyotrophic Lateral SclerosisWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Cathleen Lutz, PhD, vice president of the Rare Disease Translational Center at the Jackson Laboratory, provided comment on a recently published study which unveiled that stathmin-2 loss leads to neurofilament-dependent axonal collapse in patients with amyotrophic lateral sclerosis (ALS). Lutz offered insight on the role stathmin-2 may have in this disease, the questions that still remain, and whether restoration of stathmin-2 may be an attractive therapeutic approach. Furthermore, she spoke on the po...
2024-01-1218 minNeurologyLive® Mind Moments®Recapping Conversations in Neurology From 2023Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we comprised some of the most interesting conversations from Mind Moments podcast episodes in 2023, highlighting research in neurology that moves the field forward. The NeurologyLive team included several reaction episodes to FDA approved medicines, providing clinicians an overview of what they can expect from these new therapies and how they will be used in clinic going forward. Those included in this week's episode, in order of appearance, are:
Sharon Cohen, MD...
2023-12-2921 minNeurologyLive® Mind Moments®Effects of Once-Nightly Sodium Oxybate on Narcolepsy Type 1 and 2Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Jennifer Gudeman, senior vice president of medical and clinical affairs for Avadel Pharmaceuticals, sat down to discuss a recently published post-hoc analysis of the phase 3 REST-ON trial of once-nightly sodium oxybate (Lumryz). In the conversation, Gudeman talked about the impact of the drug on both narcolepsy types 1 and 2, the differences between these 2 subtypes, and the ways clinical trials of narcolepsy agents continue to evolve. Furthermore, she spoke on some of the unmet ne...
2023-12-1517 minNeurologyLive® Mind Moments®Advancing Epilepsy Care and Seizure Localization in PediatricsWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, William Gallentine, DO, interim chief of pediatric neurology at Stanford Medicine Children’s Health, who discussed several topics related to the advances in pediatric epilepsy, epilepsy surgery, and seizure localization. Gallentine, who also serves as a clinical professor, provided insight on the screening process and eligibility criteria for epilepsy surgery, as well as the importance of lifestyle modifications when treating epilepsy. Furthermore, he touched upon the genetic background of certain epileptic disorders and...
2023-12-0117 minNeurologyLive® Mind Moments®Potential of Gamma Sensory Stimulation in Alzheimer DiseaseWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Brent Vaughan, chief executive officer of Cognito Therapeutics, provided insight on the mechanism of action behind the company's gamma sensory stimulation as a potential therapy for patients with Alzheimer disease. He spoke on the positive phase 2 OVERTURE study presented at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference, including the notable takeaways from the trial and the safety profile observed. In addition, he commented on how this approach can be used with ne...
2023-11-1722 minNeurologyLive® Mind Moments®Special Episode: FDA Greenlights Vamorolone for Duchenne Muscular DystrophyWelcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we're covering the recent approval of vamorolone (Agamree; Santhera Pharmaceuticals) oral suspension 40 mg/mL for the treatment of patients with Duchenne muscular dystrophy (DMD) ag...
2023-11-0710 minNeurologyLive® Mind Moments®Ways to Enhance Neuromodulation in ParkinsonismWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Alfonso Fasano, MD, PhD, professor of neurology at the University of Toronto and staff neurologist at Toronto Western Hospital, who spoke on the topic of neuromodulation in Parkinson disease and the potential targets clinicians should be learning about. He discussed the specific patient profiles who fit for neuromodulation, ways to improve this type of personalized medicine, and the needed research in this patient population going forward.
Looking for more mov...
2023-11-0323 minNeurologyLive® Mind Moments®Special Episode: FDA Approves Zilucoplan for Myasthenia GravisWelcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we're covering the recent approval of zilucoplan (Zilbrysq; UCB Pharma) for the treatment of patients with acetylcholine receptor antibody–positive generalized myasthenia gravis. We spok...
2023-10-2316 minNeurologyLive® Mind Moments®2023 ECTRIMS-ACTRIMS Meeting HighlightsWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with a variety of specialists in neurology who presented research and gave talks at MSMilan, the joint ECTRIMS-ACTRIMS meeting, held October 11-13, in Milan, Italy. Those included in this week's episode, in order of appearance, are:
Mitzi Joi Williams, MD, founder and chief executive officer of the Joi Life Wellness Group Multiple Sclerosis Center.
Rhonda Voskuhl, the director of the Multiple Sclerosis Program at UCLA.
Tom Fuchs, MD, Ph...
2023-10-2015 minNeurologyLive® Mind Moments®Understanding AMX0035's Potential in Progressive Supranuclear PalsyWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Gunter Hoglinger, MD, professor of neurology and translational neuroscientist at Ludwig Maximillian's University Munich, provided commentary on a newly initiated phase 3 study assessing AMX0035 (Relyrvio; Amylyx Pharmaceuticals) in patients with progressive supranuclear palsy (PSP). Otherwise known as the ORION trial, Hoglinger discussed what went into trial inclusion, primary end points, and why they believe this therapy, which was approved for patients with amyotrophic lateral sclerosis (ALS) in 2022, could have benefits in PSP. ...
2023-10-0515 minNeurologyLive® Mind Moments®Uncovering Phenotypical Features of Narcolepsy Type 1Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Birgitte R. Kornum, MD, an associate professor in the department of neuroscience at the University of Copenhagen, discussed recently published preclinical research assessing phenotypical features and disease progression of narcolepsy type 1. Kornum provided insight on the 2 mouse models used, the effectiveness of the DVC System, and some of the phenotypic features identified. In addition, she gave insight on how the research adds to the ongoing puzzle of treating narcolepsy and where future ef...
2023-09-2217 minNeurologyLive® Mind Moments®Identifying Gaps in Access to Parkinson Disease CareWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, James Beck, PhD, senior vice president and chief scientific officer of the Parkinson's Foundation provided perspectives on a recently published Medicare claims study that highlighted major gaps and disparities in access to Parkinson disease care. He spoke on the significance of the findings, including the lack of movement disorder specialists and issues with access to mental health professionals despite high rates of depression in this patient population. Furthermore, he spoke on the wa...
2023-09-0816 minNeurologyLive® Mind Moments®Complexities With Cognitive Screening in Primary Care SettingsWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Nicole Fowler, PhD, director of research for internal medicine and geriatrics at Indiana University School of Medicine, discussed the DAVOS Alzheimer's Collaborative DIGITAL Demonstration Project, an initiative to help understand the feasibility, acceptability, and implementation of digital cognitive screening tools in primary care settings. Specifically, she spoke on how these tools will be used as more novel therapeutics for Alzheimer disease emerge, the challenges with screening patients large-scale, and how blood tests an...
2023-08-2522 minNeurologyLive® Mind Moments®Special Episode: Addition of Valbenazine to Treat Huntington Disease ChoreaWelcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we're covering the recent expanded indication of valbenazine (Ingrezza; Neurocrine Biosciences) to include the treatment of chorea associated with Huntington disease (HD). Erin Furr-Stimming, MD...
2023-08-2111 minNeurologyLive® Mind Moments®Expanding Potential for Long-Term Treatment in SMAWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Thomas Crawford, MD, a pediatric neurologist at Johns Hopkins Medicine, spoke on the recently published 5-year analysis of the NURTURE study (NCT02386553), a long-term trial assessing the efficacy and safety of nusinersen (Spinraza; Biogen) in presymptomatic infants with spinal muscular atrophy (SMA). Crawford discussed the significance of the positive findings, the shift in conversations around treatment optimization in SMA, and how subgroup data may factor into the design of future trials.
2023-08-1123 minNeurologyLive® Mind Moments®Caring for Women With Parkinson DiseaseWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Jill Farmer, DO, MPH, an assistant professor of neurology and director of the Parkinson’s Disease & Movement Disorder Program at Global Neurosciences Institute, who spoke with us about the current landscape of care for women with Parkinson disease (PD), how the approach to their care can differ from men, the major gaps around education and treatment for these women, and much more.
Looking for more Movement Disorder disc...
2023-07-1428 minNeurologyLive® Mind Moments®Special Episode: SRP-9001 Approved As First Gene Therapy for Duchenne Muscular DystrophyWelcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we're covering the recent approval of SRP-9001, or delandistrogene moxeparvovec (Elevidys; Sarepta) in Duchenne muscular dystrophy (DMD). Offering commentary is Natalie Goedeker, CPNP, a nu...
2023-06-2212 minNeurologyLive® Mind Moments®Assessing the Landscape of Sleep Disorder CareWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Ann Marie Morse, DO, FAAN, a pediatric neurologist and sleep medicine specialist at Geisinger Medical Center, who sat down with NeurologyLive at the annual SLEEP meeting to discuss the landscape of challenges narcolepsy-related challenges that patients face, the influence of gut health on sleep apnea, how nighttime disruptions can affect treatment decisions, emerging concepts of care, and much more.
Looking for more Sleep Disorder discussion? Check out th...
2023-06-1619 minNeurologyLive® Mind Moments®Raising Stroke Awareness and Improving Clinical CareWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Brandon Giglio, MD, a vascular neurologist and clinical assistant professor of neurology at NYU Grossman School of Medicine, as well as the director of Vascular Neurology at NYU Langone Hospital in Brooklyn, New York. As May is annually designated as Stroke Awareness Month in the United States, Giglio sat down with us to extend that time of awareness and share his insight into the current public understanding of stroke, ho...
2023-06-0217 minNeurologyLive® Mind Moments®Potential of CNM-Au8 Gold Nanocrystals to Treat ALSWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with James Berry, MD, PhD, director of the Massachusetts General Hospital ALS Care Center. At the 2023 American Academy of Neurology Annual Meeting, he spoke about new data from a study assessing CNM-Au8, a nanocrystal formulation in development for patients with ALS and other neurological diseases. Additionally, he talked about the current unmet needs in the ALS community, including the need for more diverse treatment options and increased research.
Loo...
2023-05-1913 minNeurologyLive® Mind Moments®Special Episode: Tofersen Approved for SOD1 ALSWelcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we're covering the recent approval of tofersen (Qalsody; Biogen/Ionis) in SOD1 mutation-mediated amyotrophic lateral sclerosis (ALS). Offering commentary is Angela Genge, MD, FRCPC, th...
2023-04-2512 minNeurologyLive® Mind Moments®Pimavanserin and Atypical Antipsychotics to Treat Parkinson Disease PsychosisWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Dilesh Doshi, PharmD, vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals. He spoke on the advantages and benefits of pimavanserin (Nuplazid; Acadia), the only FDA-approved therapy to treat Parkinson disease psychosis. Additionally, he discussed recent data that compared efficacy and safety of other off-label therapies such as clozapine and quetiapine.
Looking for more Parkinson disease discussion? Check out the NeurologyLive® movement disorder clinical focus page...
2023-04-0721 minNeurologyLive® Mind Moments®Impact of Narcolepsy on Social Relationship Health in AdolescentsWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Eric Zhou, PhD, assistant professor of pediatrics at Harvard Medical School. He spoke on a recently conducted study assessing the link between narcolepsy in adolescents and social relationship health. Specifically, he talked about how the sleep disorder impacts mood, physical activities, driving, and other long-term health outcomes, as well as ways we can help adolescents with narcolepsy at the earliest stages.
Looking for more narcolepsy discussion? Check out...
2023-03-2414 minNeurologyLive® Mind Moments®Special Episode: Trofinetide Approved for Rett SyndromeWelcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we're covering the recent approval of trofinetide (Daybue; Acadia) in Rett syndrome. Offering commentary is Jeffrey L. Neul, MD, PhD, the Annette Schaffer Eskind Ch...
2023-03-1311 minNeurologyLive® Mind Moments®Parkinson Disease Education for Community ProvidersWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Elizabeth “Eli” Pollard, vice president & chief education and training officer at the Parkinson's Foundation, and the executive director of the World Parkinson Coalition. She spoke about the foundation's ongoing efforts in providing education about Parkison disease (PD), the challenges of managing a growing population of patients, the need for community physicians and specialists to work in unison, and more.
>>Click here to access the Parkinson Foundation's educational series...
2023-03-1030 minNeurologyLive® Mind Moments®The ARISE Study and Using DMTs in RISWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Darin Okuda, MD, director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center. He spoke about the phase 2 ARISE study assessing dimethyl fumarate (Tecfidera; Biogen) in patients with radiologically isolated syndrome, the significance of the findings, next steps in validating this therapy, and more.
Looking for more multiple sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page.
Episode Breakdown:
1:20 – Overvi...
2023-02-2420 minNeurologyLive® Mind Moments®Managing Seizures After Ischemic StrokeWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Carolina Ferreira Atuesta, MD, MSc, a scientific researcher and clinical data manager at the Icahn School of Medicine at Mount Sinai. She spoke about research she and colleagues recently presented at the American Epilepsy Society Annual Meeting on poststroke epilepsy, the ongoing clinical efforts to manage seizures occurring after stroke, what studies still need to explore, and more.
Looking for more epilepsy discussion? Check out the NeurologyLive® epi...
2023-02-1025 minNeurologyLive® Mind Moments®Widening the Therapeutic Window in Parkinson DiseaseWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida. He spoke about the current state of therapeutics in Parkinson disease (PD), some of the lingering challenges in day-to-day management, the promise of novel agents in development such as IPX203, and more.
Looking for more movement disorder discussion? Check out the NeurologyLive® movement disorder clinical focus page, or fo...
2023-01-2720 minNeurologyLive® Mind Moments®Advancing Treatment for Rare Neuromuscular DisordersWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Sarah Boyce, president and CEO of Avidity Biosciences, who shared insight into the company's ongoing work with its antibody oligonucleotide conjugates (AOC) platform and the focus on myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD) treatments, as well as the challenges with developing successful RNA therapies, and more.
Looking for more neuromuscular disorder discussion? Check out the NeurologyLive® neuromuscular clinical focus page: neu...
2023-01-1320 minNeurologyLive® Mind Moments®Special Episode: Lecanemab Approved for Alzheimer DiseaseWelcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In 2022 and onward, whenever the FDA makes a major decision for the field of neurology, we'll be releasing short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we're covering the recent approval of lecanemab (Leqembi; Eisai) in Alzheimer disease. Offering commentary is Sharon Cohen, MD...
2023-01-0914 minNeurologyLive® Mind Moments®A New Monoclonal for Alzheimer DiseaseWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Marwan Sabbagh, MD, FAAN, a behavioral neurologist at the Barrow Neurological Institute. He joined the show to discuss the clinical trial results for lecanemab that were presented at the Clinical Trials on Alzheimer’s Disease meeting in San Francisco, the drug’s overall efficacy profile, as well safety information and the rates of ARIA, and more.
Lecanemab (Biogen/Eisai), is a humanized monoclonal antibody that eliminates toxic amyloi...
2022-12-1621 minNeurologyLive® Mind Moments®A Virtual Reality Platform for Parkinson DiseaseWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic. He joined the show to discuss the complexities that come with understanding early signs of PD, and how the newly designed Cleveland Clinic Virtual Reality Shopping (also known as CC-VRS) platform works towards improving that, among other topics.
Looking for more Parkinson disease discussion? Check out the NeurologyLive® movement disorders clinical focus pag...
2022-12-0227 minNeurologyLive® Mind Moments®A New Era of Myasthenia Gravis TreatmentWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with George Small, MD, an adult neurologist at Allegheny Health Network, who discussed the state of care for myasthenia gravis and its recent success, the corresponding changes to patient care, and the current era of treatment that the field has entered, among other topics.
Looking for more myasthenia gravis discussion? Check out this NeurologyLive® Peers & Perspectives series, featuring James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAA...
2022-11-1833 minNeurologyLive® Mind Moments®Special Episode: Aducanumab and Anti-Amyloid-ß, One Year LaterWelcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we mark 1 year since the FDA granted accelerated approval to aducanumab (Aduhelm; Biogen), the first approval in Alzheimer disease since 2003. This episode offers an abridged recap of the events that have taken place over the course of its clinical journey, and in the year since that decision. Later this month, the June 2022 issue of NeuologyLive® will include a cover story that features a more in-depth and extensive review of the aducanumab saga and...
2022-06-0710 minNeurologyLive® Mind Moments®Special Episode: Ganaxolone Approved for CDD, Fenfluramine Approved for LGSWelcome to this special episode of the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In 2022 and onward, whenever the FDA makes a major decision for the field of neurology, we'll be releasing short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we're covering the recent approvals of ganaxolone (Ztalmy; Marinus Pharmaceuticals) in cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, also kno...
2022-03-3021 minNeurologyLive® Mind Moments®Invisible Symptoms: Cognition and MSWelcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Dhanashri P. Miskin, MD, clinical assistant professor of neurology, Thomas Jefferson University Hospitals. She offered her insight into the role that cognitive impairment plays as a symptom of multiple sclerosis (MS), the current approach to treatment and management for patients, and what challenges remain for the field to address.
Episode Breakdown:
1:25 – Background on cognitive symptoms of MS
4:25 – Prevalence of cognitive issues for patients
6:05 – Current understanding of the driving f...
2022-02-1139 minNeurologyLive® Mind Moments®Epstein-Barr Virus's Relationship With Multiple SclerosisWelcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Bridget A. Bagert, MD, MPH, director, Ochsner Multiple Sclerosis Center, and an investigator in the clinical study of the Epstein-Barr virus (EBV)-targeted agent, ATA188 (Atara Biotherapeutics). She offered her perspective on the recent data from Ascherio et al on the relationship between EBV and multiple sclerosis (MS) that suggest it may be a root cause of the disease, as well as background on the decades of research that hav...
2022-01-2832 minNeurologyLive® Mind Moments®Special Episode: Daridorexant Approved for InsomniaWelcome to this special episode of the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In 2022 and onward, whenever the FDA makes a major decision for the field of neurology, we'll be releasing short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.
In this episode, we're covering the recent approval of daridorexant (Quviviq; Idorsia) for the treatment of insomnia. Offering commentary is Tho...
2022-01-1112 minNeurologyLive® Mind Moments®Is Telehealth Here to Stay for Alzheimer Disease Care?Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Jessica Zwerling, MD, MS, director of the Montefiore Hudson Valley Center of Excellence for Alzheimer's Disease, to find out more about the role that telehealth may play in the future care of Alzheimer and dementia. She shared her experience with it in the last year and offered insight into how it can affect access and impact social determinants of health.
The stories feature in this week's Neurology...
2021-07-3024 minNeurologyLive® Mind Moments®Consensus MRI Guidelines for MSWelcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Scott D. Newsome, DO, president, Consortium of Multiple Sclerosis Centers (CMSC), director, Neurosciences Consultation and Infusion Center at Green Spring Station, and associate professor of neurology, Johns Hopkins Medicine; and David Li, MD, FRCPC, professor of radiology, associate member in neurology, and director, Multiple Sclerosis/MRI Research Group, University of British Columbia. The pair spoke about the recent consensus guidelines that were published and developed by the Magnetic Resonance...
2021-07-0234 minNeurologyLive® Mind Moments®A Controversial FDA DecisionWelcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with a number of people in the Alzheimer disease field with varying and nuanced opinions on this decision to better understand not only what this approval means for the clinical care of patients, but what the downstream effects of it may be. Those individuals, in order of appearance, are:
Marwan Sabbagh, MD, director, Cleveland Clinic Lou Ruvo Center for Brain Health, and investigator in the aducanumab trials
Anton P. Porsteinsson, M...
2021-06-1131 minNeurologyLive® Mind Moments®Highlights From the AAN Annual MeetingWelcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD. Each of them discussed data that they respectively presented at the American Academy of Neurology Annual Meeting. These presentations included novel tools for tracking cognitive decline, analyses of subpopulations of patients with migraine treated with new medicines, the disparities faced by women and Black individuals...
2021-04-3036 minNeurologyLive® Mind Moments®The Multiple Sclerosis Patient JourneyWelcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we feature a portion of our NeurologyLive Cure Connections series, “Multiple Sclerosis Patient Journey,” put on in partnership with the Consortium of Multiple Sclerosis Centers (CMSC). It features a diverse panel of people including Patricia K. Coyle, MD, an expert neurologist; Frederick Foley, PhD, a clinical psychologist; Ann Moore, a patient with MS; and her partner, Kathe Zelles. Moderated by June Halper, MSN, MSCN, the group shares their perspectives and experiences on vari...
2021-01-2917 minNeurologyLive® Mind Moments®Taking Steps to Advance Sleep CareWelcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we're joined by Raman Malhotra, MD, associate professor of neurology, Washington University in St. Louis, and board of directors, American Academy of Sleep Medicine. He detailed some of the advances in therapy and research in sleep medicine and highlighted some of the challenges faced by sleep specialists.
Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to...
2020-10-2316 minNeurologyLive® Mind Moments®The Vascular Implications of Alzheimer DiseaseWelcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we're joined by Costantino Iadecola, MD, Anne Titzell Professor of Neurology, and director and chair, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine. He discussed the shortcomings of the current clinical approach to Alzheimer disease and offered insight into how vascular risk factors play a role in its pathology.
Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe...
2020-10-0923 minNeurologyLive® Mind Moments®Preventing Tonic-Clonic Seizures in Refractory EpilepsyWelcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we're joined by David Vossler, MD, professor, and medical director, The Neuroscience Institute, UW Medicine Valley Medical Center. He discussed the findings of a recently published phase 3 dataset on lacosamide, also known as Vimpat, and its effects on reducing genetic generalized onset tonic-clonic seizures.
Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news an...
2020-09-2522 minNeurologyLive® Mind Moments®The Metamorphosis of Migraine: Discovery and DevelopmentWelcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
This episode is the first part of a 3-part multimedia series from NeurologyLive on the metamorphosis of migraine care. In this episode, we're joined by Stewart Tepper, MD, director of research, Dartmouth Headache Clinic, and professor of neurology, Dartmouth Giesel School of Medicine. He offers insight into how migraine care has evolved since the 1990s thanks to a number of scientific discoveries and the therapeutic developments that followed.
Thanks for listening to the NeurologyLive Mind...
2020-09-1129 min
NeurologyLive® Mind Moments®Personalizing Our Approach to Medication Adherence in Parkinson DiseaseWelcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we're joined by Rajesh Pahwa, MD, the Laverne and Joyce Rider Professor of Neurology; chief of the Parkinson’s and Movement Disorder Division; and director of the Parkinson's Foundation Center for Excellence at the University of Kansas Medical Center. He offers insight into the challenges of medication adherence in Parkinson disease and how it impacts OFF episode management.
Thanks for listening to the NeurologyLive Mind Moments podcast. For more neurology news and ex...
2020-08-2816 minNeurologyLive® Mind Moments®A New Approval: The SMA Treatment LandscapeWelcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Richard Finkel, MD, a pediatric neurologist and recently named head of the new Center for Experimental Neurotherapeutics at St. Jude Children’s Research Hospital. Finkel offered an in-depth look at how the recent FDA approval of oral risdiplam (Evrysdi; Roche) might impact the spinal muscular atrophy (SMA) therapeutic landscape.
Thanks for listening to the NeurologyLive Mind Moments podcast. For more neurology news and expert-driven content, visit neurologylive.com.
2020-08-1420 minNeurologyLive® Mind Moments®Trends in the Alzheimer Clinical PipelineWelcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we're joined by Dr. Jeffrey Cummings, the director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and the vice-chair of the Department of Brain Health at the University of Nevada–Las Vegas. Dr. Cummings shared his insight into a recent review he and colleagues did of the trends in the Alzheimer Disease pipeline.
Thanks for listening to the NeurologyLive Mind Moments podcast. For more neurology news and expert-driven content, visi...
2020-07-3113 minNeurologyLive® Mind Moments®Sequencing SNPs in Huntington DiseaseWelcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we’re joined by Dr. Daniel Claassen, an associate professor of neurology in the Department of Cognitive and Behavioral Neurology and Movement Disorders at Vanderbilt University. Dr. Claassen discussed the recent work he and colleagues did in assessing the feasibility of conducting clinical trials using therapies that target single nucleotide polymorphisms, or SNPs, in patients with Huntington disease.
Thanks for listening to the NeurologyLive Mind Moments podcast. For more neurology news and expert-driven content, visit n...
2020-07-1715 min